ArticleAntimicrobial agents and chemotherapy2004
Inhibitors of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Resistance breakers: a novel approach to tackle biofilm associated infections and antimicrobial resistance.Frontiers in microbiology · 2026Review
- Intestinal mucus acts as a nutrient source and signal forMicrobiome research reports · 2026Article
- 1-(1-naphthylmethyl)-piperazine Inhibition assay successfully rules out efflux pump overexpression in Acinetobacter baumannii.Molecular biology reports · 2025Article
- Antibiotic-induced stress responses in Gram-negative bacteria and their role in antibiotic resistance.The Journal of antimicrobial chemotherapy · 2025Review
- Identification of Potential Inhibitors of Three NDM Variants ofCurrent computer-aided drug design · 2025Article
- Bacterial Efflux Pump Inhibitors Reduce Antibiotic Resistance.Pharmaceutics · 2024Review
- Efflux pumps as potential targets for biofilm inhibition.Frontiers in microbiology · 2024Review
- Article
- Medicinal Chemistry of Inhibitors Targeting Resistant Bacteria.Current topics in medicinal chemistry · 2022Article
- Microbial Efflux Pump Inhibitors: A Journey around Quinoline and Indole Derivatives.Molecules (Basel, Switzerland) · 2021Review
- Efflux Pump Overexpression Profiling in Acinetobacter baumannii and Study of New 1-(1-Naphthylmethyl)-Piperazine Analogs as Potential Efflux Inhibitors.Antimicrobial agents and chemotherapy · 2021Article
- Molecular Insights into an Antibiotic Enhancer Action of New Morpholine-Containing 5-Arylideneimidazolones in the Fight against MDR Bacteria.International journal of molecular sciences · 2021Article
- Complete Genome Sequence of Klebsiella aerogenes Siphophage Solomon.Microbiology resource announcements · 2021Article
- Efficiency of a Tetracycline-Adjuvant Combination Against Multidrug ResistantAntibiotics (Basel, Switzerland) · 2020Article
- Effectiveness of Efflux Pump Inhibitors as Biofilm Disruptors and Resistance Breakers in Gram-Negative (ESKAPEE) Bacteria.Antibiotics (Basel, Switzerland) · 2019Review
- Efflux pumps and antimicrobial resistance: Paradoxical components in systems genomics.Progress in biophysics and molecular biology · 2019Review
- Interplay Between the Phenotype and Genotype, and Efflux Pumps in Drug-Resistant Strains ofFrontiers in microbiology · 2018Article
- DNA Damage Repair and Drug Efflux as Potential Targets for Reversing Low or Intermediate Ciprofloxacin Resistance inFrontiers in microbiology · 2018Article
- Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps.Current medicinal chemistry · 2016Review
- The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.Clinical microbiology reviews · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Enterobacter aerogenes and Klebsiella pneumoniae, efflux provides efficient extrusion of antibiotics and contributes to the multidrug resistance phenotype. One of the alkoxyquinoline derivatives studied here, 2,8-dimethyl-4-(2'-pyrrolidinoethyl)-oxyquinoline, restores noticeable drug susceptibility to resistant clinical strains. Analyses of energy-dependent chloramphenicol efflux indicate that this compound inhibits the efflux pump mechanism and improves the activity of structurally unrelated antibiotics on multidrug-resistant E. aerogenes and K. pneumoniae isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.